



Curetis Announces Management Board Changes

- New roles for Andreas Boos, Chris Bernard and Dr. Achim Plum

Amsterdam, the Netherlands, and Holzgerlingen, Germany, August 16, 2017; published at 7 am CET -- Curetis N.V. (the "**Company**" and, together with Curetis GmbH, "**Curetis**"), a developer of next-level molecular diagnostic solutions, today announced several changes in its Management Board, effective as of today.

Andreas Boos, CTO and co-founder of Curetis, is stepping down from the Management Board of Curetis N.V. to focus on his role as the group's CTO and program director for the Gyrnimo platform development. Andreas will continue to serve as one of the managing directors of Curetis GmbH. This move is part of the continuing evolution of Curetis' organization towards a more commercially driven enterprise.

Chris Bernard, President and CEO of Curetis USA Inc, has been appointed as Executive VP of Global Sales, assuming direct management responsibility for the EMEA sales organization. He will report directly to Curetis N.V. CEO Oliver Schacht and will inform the Supervisory Board on all sales-related matters.

Dr. Achim Plum, COO of Curetis, will assume the role of Chief Business Officer (CBO) for Curetis N.V. He will continue to lead EMEA marketing, customer service & support, scientific affairs, and global business development. In addition, he is serving as one of the managing directors of Ares Genetics GmbH in Vienna to accelerate and drive the partnering and development of GEAR related programs forward.

"The changes in our Management Board reflect the increasing commercial focus of the company," said Dr. Oliver Schacht, CEO of Curetis. "The new roles and responsibilities of Andreas, Chris and Achim will enable us to maximize the value of our recent product and technology additions."

Disclaimer

CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.

###

About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a

process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia. In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.

For further information, please visit www.curetis.com.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com - www.unyvero.com

International Media & Investor Inquiries

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries

The Ruth Group

Lee Roth

lroth@theruthgroup.com

Tel. +1 646 536 7012